Inclusion Criteria

  1. Diagnose von rheumatoider ArthritisThe diagnosis RA is made by the rheumatologist taking into account the classification criteria of the American College of Rheumatology (ACR).
    Not suitable for inclusion in RABBIT are patients with arthritis in the context of another autoimmune disease in the foreground, such as collagenosis or vasculitis.
  2. Age of onset of the disease 16 years and older
  3. Inclusion in the group of biologics / biosimilar / JAK inhibitor patients  Start of a new therapy or a new therapy cycle with a biologic / biosimilar / JAK inhibitor approved for RA
    • after failure of at least one therapy with a conventional DMARD or
    • after failure of a previous therapy with a biologic/biosimilar/JAK inhibitor

    Restart of therapy with a biologic/biosimilar/JAK inhibitor after at least a three-month therapy break.

    Since 01.01.2017, patients who receive Remicade® can no longer be included in RABBIT. Patients who receive Remicade® at a follow-up measuring point will continue to be monitored in RABBIT.

  4. Inclusion in the control group Start of a new therapy with a conventional DMARD after failure of at least one therapy with a conventional DMARD.
Therapy / conventional DMARDs /1987 ACR Criteria

Biologics, biosimilars and JAK inhibitors currently used to enroll patients in RABBIT

BIOLOGIKA BIOSIMILARS JAK-INHIBITOREN
Cimzia® (Certolizumab)
Enbrel® (Etanercept)
Humira® (Adalimumab)
Kevzara® (Sarilumab)
MabThera® (Rituximab)
Orencia® (Abatacept)
RoACTEMRA® (Tocilizumab)
Simponi® (Golimumab)
Benepali® (Etanercept-Biosimilar)
Erelzi® (Etanercept-Biosimilar)
Flixabi® (Infliximab-Biosimilar)
Remsima® (Infliximab-Biosimilar)
Rixathon® (Rituximab-Biosimilar)
Olumiant® (Baricitinib)
Xeljanz® (Tofacitinib)

Examples for conventional DMARDs

Methotrexat
Leflunomid
Sulfasalazin
Hydroxychloroquin/ Chloroquin
Azathioprin
Cyclosporin A

1987 ACR Criteria

  1. morning stiffness in and around joints for at least 60 minutes before maximum improvement
  2. Swelling as a sign of arthritis in at least three of fourteen joints,
  3. objectified by a doctor (metacarpophalangeal joints on both sides, proximal interphalangeal joints, hand, elbow, knee, ankle and metatarsophalangeal joints)
  4. swelling as a sign of arthritis of the proximal interphalangeal, metacarpophalangeal or wrist joints
  5. symmetrical arthritis
  6. Detection of rheumatic nodules
  7. Detection of rheumatoid factors
  8. Radiological detection of erosions and/or periarticular osteopenia